Bays HE - Search Results

1

An assessment by the Statin Intolerance Panel: 2014 update.

Guyton JR, Bays HE, Grundy SM, Jacobson TA, The National Lipid Association Statin Intolerance Panel. Guyton JR, et al. Among authors: bays he. J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S72-81. doi: 10.1016/j.jacl.2014.03.002. J Clin Lipidol. 2014. PMID: 24793444

2

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.

Kashyap ML, McGovern ME, Berra K, Guyton JR, Kwiterovich PO, Harper WL, Toth PD, Favrot LK, Kerzner B, Nash SD, Bays HE, Simmons PD. Kashyap ML, et al. Among authors: bays he. Am J Cardiol. 2002 Mar 15;89(6):672-8. doi: 10.1016/s0002-9149(01)02338-4. Am J Cardiol. 2002. PMID: 11897208 Clinical Trial.

3

Statin safety: an overview and assessment of the data--2005.

Bays H. Bays H. Am J Cardiol. 2006 Apr 17;97(8A):6C-26C. doi: 10.1016/j.amjcard.2005.12.006. Epub 2006 Feb 8. Am J Cardiol. 2006. PMID: 16581330 Review.

4

Safety considerations with niacin therapy.

Guyton JR, Bays HE. Guyton JR, et al. Among authors: bays he. Am J Cardiol. 2007 Mar 19;99(6A):22C-31C. doi: 10.1016/j.amjcard.2006.11.018. Epub 2006 Nov 28. Am J Cardiol. 2007. PMID: 17368274 Review.

5

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia.

Bays HE, Jones PH, Mohiuddin SM, Kelly MT, Sun H, Setze CM, Buttler SM, Sleep DJ, Stolzenbach JC. Bays HE, et al. J Clin Lipidol. 2008 Dec;2(6):426-35. doi: 10.1016/j.jacl.2008.10.001. Epub 2008 Nov 12. J Clin Lipidol. 2008. PMID: 21291776

6

Drugs in development for management of lipoprotein disorders.

Brown WV, Bays H, Davidson M, Goldberg A. Brown WV, et al. J Clin Lipidol. 2011 Mar-Apr;5(2):66-75. doi: 10.1016/j.jacl.2011.01.004. Epub 2011 Jan 28. J Clin Lipidol. 2011. PMID: 21392719 No abstract available.

7

Planning a clinical trial.

Brown WV, Bays HE, Maki KC, Wild RA. Brown WV, et al. Among authors: bays he. J Clin Lipidol. 2012 Nov-Dec;6(6):484-95. doi: 10.1016/j.jacl.2012.10.001. Epub 2012 Oct 5. J Clin Lipidol. 2012. PMID: 23312046 Review. No abstract available.

8

Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association.

Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, Gonzalez-Campoy JM, Jones SR, Kumar R, La Forge R, Samuel VT. Bays HE, et al. J Clin Lipidol. 2013 Jul-Aug;7(4):304-83. doi: 10.1016/j.jacl.2013.04.001. Epub 2013 May 31. J Clin Lipidol. 2013. PMID: 23890517

9

An assessment by the Statin Liver Safety Task Force: 2014 update.

Bays H, Cohen DE, Chalasani N, Harrison SA, The National Lipid Association's Statin Safety Task Force. Bays H, et al. J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S47-57. doi: 10.1016/j.jacl.2014.02.011. J Clin Lipidol. 2014. PMID: 24793441

10

National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. Jacobson TA, et al. Among authors: bays he. J Clin Lipidol. 2014 Sep-Oct;8(5):473-88. doi: 10.1016/j.jacl.2014.07.007. Epub 2014 Jul 15. J Clin Lipidol. 2014. PMID: 25234560 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

294 results

Search Page